Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Springworks Therapeutics Inc (NQ: SWTX )

36.55 +0.34 (+0.94%)
Streaming Delayed Price Updated: 3:16 PM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Springworks Therapeutics Inc

< Previous 1 2 3 Next >
SWTX Stock Earnings: SpringWorks Therapeutics Meets EPS, Beats Revenue for Q1 2024
SWTX stock results show that SpringWorks Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
SpringWorks Therapeutics: Q4 Earnings Insights
Via Benzinga
Why SpringWorks Therapeutics Stock (SWTX) Is Nosediving
SpringWorks Therapeutics Inc (NASDAQ: SWTX) shares are trading lower by 8.4% to $29.00 Tuesday morning after the company announced the pricing of a publ 
Via Benzinga
Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Titan Machinery Inc. (NASDAQ: TITN) moved lower during Thursday’s trading following weak quarterly results. 
Via Benzinga
Analyst Ratings for SpringWorks Therapeutics
Via Benzinga
La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 200 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Analyst Ratings for SpringWorks Therapeutics
Via Benzinga
Analyst Ratings for SpringWorks Therapeutics
Via Benzinga
SpringWorks Catapults 24% On A 'Watershed Moment' In Cancer Treatment
The company gained FDA approval for Ogsiveo, a treatment for desmoid tumors. 
Via Investor's Business Daily
Exposures Product Safety
PDD Posts Upbeat Revenue, Joins Avidity Biosciences, SpringWorks Therapeutics And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults... 
Via Benzinga
Exposures Product Safety
FDA Approves SpringWorks Therapeutics' Lead Therapy As First For Subtype Of Soft Tissue Sarcomas
The FDA approved SpringWorks Therapeutics Inc's (NASDAQ: SWTX) Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who  
Via Benzinga
Exposures Product Safety
The Latest Analyst Ratings for SpringWorks Therapeutics
Via Benzinga
SpringWorks Therapeutics: Q1 Earnings Insights
Via Benzinga
Analyst Expectations for SpringWorks Therapeutics's Future
Via Benzinga
4 Analysts Have This to Say About SpringWorks Therapeutics
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for SpringWorks Therapeutics: Here's What You Need To Know
Via Benzinga
What's Going On With Rare Diseases-Focused SpringWorks Therapeutics Stock Today?
SpringWorks Therapeutics Inc (NASDAQ: SWTX) released topline results from its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with... 
Via Benzinga
SpringWorks' Investigational Cancer Treatment Is Standard Care, Analyst Unfazed By FDA Update
In March, the FDA issued SpringWorks Therapeutics Inc (NASDAQ: SWTX) with a Form 483 letter due to a failure to ensure that the analysis of an exploratory endpoint in the Phase 3 DeFi trial, which... 
Via Benzinga
Exposures Product Safety
Get In Now. 7 Stocks That Are Set to Soar.
While it’s always difficult to determine which stocks to buy might break out imminently, speculators should watch these ideas. 
Via InvestorPlace
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
Analyst Ratings for SpringWorks Therapeutics
Within the last quarter, SpringWorks Therapeutics (NASDAQ:SWTX) has observed the following analyst ratings: 
Via Benzinga
SpringWorks Shares Pop After Expanded Multiple Myeloma Pact With GSK
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
SpringWorks Therapeutics: Q3 Earnings Insights
SpringWorks Therapeutics (NASDAQ:SWTX) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
NIO, Lucid Group And Other Big Gainers From Monday
U.S. stocks closed higher with the Dow Jones surging more than 200 points on Monday. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.